Laidlaw & Company, a UK-based brokerage firm, has sold securities of Relmada Therapeutics, a biopharmaceutical company purportedly developing therapies for central nervous system (CNS) disorders. Relmada claims to be developing four products: d-Methadone (dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist for depression and neuropathic pain, which they hope will become a fast-acting treatment for depression. …

Read More